Video Experimental Relacionado
Updated: Feb 24, 2026
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
17.1K
Eje de la Enfermedad Hepática Estetósica Asociada a Disfunción Metabólica-Enfermedad Renal Crónica: Vías de
Sriram Sriperumbuduri1, Prathab Balaji Saravanan2, Gaurav Gupta1
1Division of Nephrology, Virginia Commonwealth University Health System, Richmond, Virginia, USA.
Kidney international reports
|February 23, 2026
Resumen
La enfermedad renal crónica (ERC) y la enfermedad hepática esteatósica asociada a disfunción metabólica (EHDM) coexisten con frecuencia, lo que aumenta los riesgos para la salud. El manejo de los factores metabólicos es clave para la detección temprana de la ERC en pacientes con EHDM.
Área de la Ciencia:
- Nefrología
- Hepatología
- Enfermedades Metabólicas
Sus antecedentes:
- La enfermedad renal crónica (ERC) y la enfermedad hepática esteatósica asociada a disfunción metabólica (EHDM) son problemas de salud globales prevalentes.
- La EHDM afecta a casi un tercio de los adultos y se asocia con un mayor riesgo de enfermedad cardiovascular, enfermedad renal y cáncer.
- La ERC afecta a más de 650 millones de personas en todo el mundo, representando una causa importante de enfermedad y muerte.
Objetivo del estudio:
- Revisar la evidencia epidemiológica y mecanicista que vincula la EHDM y la ERC.
- Discutir las implicaciones clínicas, el cribado y las estrategias de manejo para la coexistencia de EHDM y ERC.
- Destacar la necesidad de atención multidisciplinaria e investigación adicional.
Principales métodos:
- Revisión sistemática de estudios epidemiológicos y mecanicistas.
- Síntesis de la evidencia sobre factores de riesgo compartidos y vías fisiopatológicas.
- Análisis de las implicaciones clínicas para el cribado y el manejo.
Principales resultados:
- Estudios muestran una mayor prevalencia de ERC en pacientes con EHDM, particularmente con enfermedad hepática avanzada.
- Mecanismos compartidos incluyen resistencia a la insulina, inflamación y factores metabólicos (obesidad, hipertensión, diabetes).
- Estos factores contribuyen a la lesión renal en individuos con EHDM.
Conclusiones:
- La superposición entre EHDM y ERC requiere enfoques de atención multidisciplinaria.
- La identificación temprana de la ERC en pacientes con EHDM y el manejo agresivo de los factores de riesgo metabólico son cruciales.
- Se necesita más investigación para optimizar el cribado, comprender las vías y mejorar el tratamiento.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
225
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
225
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
273
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
273
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
228
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
228
01:28Chronic Kidney Disease III: Interprofessional Care
503
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
503
01:24Overview of Lipid Metabolism
6.0K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
6.0K
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
256
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
256